ATG5

Across TCGA pan-cancer cohorts, ATG5 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ATG5 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ATG5 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ATG5 expression acts as an unfavorable survival marker, although some lineages such as HNSC and PDAC show a favorable association.

HNSC, PDAC, and CCRCC are the cancer types where ATG5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	All	0.858	0.212	.010	27	view →
PDAC	OS	Quartile	II,III,IV	0.627	0.255	<.001	24	view →
CCRCC	DFS	Median	All	0.603	0.876	.002	14	view →
UCEC	DFS	Tertile	All	1.000	0.854	.004	10	view →
LUAD	OS	Median	II,III,IV	0.507	0.893	.046	4	view →
GBM	DFS	Median	All	0.195	0.326	.008	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ATG5–HNSC (DFS)

Open the HNSC breakdown →